Tag: investor

DUBLIN, July 23, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (NASDAQ: HTOO) (“Fusion Fuel” or the “Company”), a provider of integrated energy solutions, today announced that it has received the first payment related to its sale of its former 50% equity interest in P2X Spain Sociedad Limitada (formerly known as Fusion Fuel Spain, S.L.) (“P2X Spain”) to EREE Desarrollos Empresariales, S.L. (“EREE”).

Expands global leadership team; appoints Christopher Merrill, Global CEO

Exploring Digital Asset Strategies to Inform Future Capital Innovation

Rogers delivers strong results and completion of transformational investments in the second quarter

PHOENIX, July 23, 2025 (GLOBE NEWSWIRE) -- Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) announced that it filed a registration statement on Form S-4 and S-1 with the U.S. Securities and Exchange Commission (“SEC”) on July 10, 2025 in connection with the Company's proposed merger (the “Merger”) with Republic Airways Holdings Inc. (“Republic”). The registration statement includes a proxy statement and preliminary prospectus. Once declared effective by the SEC, the final proxy statement/prospectus included in the Form S-4/Form S-1 will be mailed to the Mesa stockholders prior to their vote on the proposed Merger.

October 3, 2025 payment date following September 8, 2025 record date

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.